A connectomics company that helps neurosurgeons see which parts of a patient’s brain control language and movement before they operate has raised $27 million, and is using the round to expand into brain-computer interface adjacencies. Omniscient Neurotechnology (o8t) closed a $27.2 million (AU$41.1 million) Series D round on 29 May 2026, co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation, with continued support from Will Vicars and Gina Rinehart AO. The company explicitly named brain-computer interface, stroke, and movement disorders as the next markets the capital will fund expansion into. Omniscient itself is not a BCI implant company. Its current product is Quicktome, an FDA-cleared connectomics platform that maps individual patients’ brain networks for neurosurgical planning. The BCI angle in the round announcement is forward-looking adjacency rather than current product.

What Omniscient actually does

The current Omniscient product is Quicktome, an FDA-cleared software platform that generates patient-specific connectomic maps. The maps visualise the functional brain regions and the white-matter pathways responsible for language, movement, and cognition. The clinical use case sits inside the pre-surgical planning workflow: neurosurgeons performing complex brain surgery (typically tumour resection or epilepsy work) use Quicktome to understand which white-matter tracts they need to avoid disrupting in order to preserve language, motor function, and other capacities. The company’s positioning frame is “Google Maps for the Brain,” articulated by OIF Ventures partner David Shein in the round announcement.

Quicktome received FDA 510(k) clearance in 2021 and is currently in use across major US healthcare networks, including Hackensack Meridian Neuroscience Institute. The technology is also cleared in Canada and Australia. The company recently received CPT code 1039T from the American Medical Association, establishing a billing pathway for connectomic analysis under the US healthcare reimbursement system. The CPT code is the underlying reason a Series D is feasible at this point: with a billing code in place, the platform has a path to recurring procedure-linked revenue from US hospital networks.

How BCI fits into the strategic frame

The Globe Newswire round announcement names BCI, stroke, and movement disorders as the high-growth markets the capital will fund expansion into. The BCI adjacency is structurally credible. Quicktome’s underlying connectomic mapping technology is exactly the architecture that an invasive BCI implant pre-surgical planning workflow needs: high-resolution white-matter and functional area mapping to identify safe trajectories for cortical electrode placement and to anticipate which functional regions a particular electrode array geometry will record from or stimulate.

For the clinical-stage BCI cohort (Synchron, Neuralink, Paradromics, Precision Neuroscience, NeuroXess, ABILITY, Neuracle, BrainGate consortium sites), a connectomic pre-surgical planning tool is a complementary infrastructure layer rather than a competing product. The Omniscient pivot into BCI adjacency would position the company as a clinical-decision-support and surgical-planning vendor to the BCI implant cohort, rather than as a BCI company itself. The investor framing of “global standard of care” suggests the company is targeting integration into hospital networks as the entry point, with BCI implant company partnerships as a downstream extension.

The investor base

The Series D is heavily Australian-anchored, which fits Omniscient’s history as a Sydney-founded company with San Francisco commercial operations. Co-leads are OIF Ventures (Australian venture firm) and the Australian National Reconstruction Fund Corporation (NRFC), the federal sovereign fund established by the Albanese government to support strategic Australian industrial capacity. Continuing investors include Will Vicars (founder of Caledonia Investments) and Gina Rinehart AO (Hancock Prospecting). The NRFC’s participation is structurally notable: federal Australian sovereign capital is directly backing a connectomics-and-BCI-adjacent company that operates internationally, which aligns with the broader Australian neurotech industrial-policy narrative that has supported Synchron’s roots in Melbourne neuroscience.

CEO Stephen Scheeler has led the company through the transition from FDA-cleared platform launch to commercial scale, and frames the round as “scaling AI-driven precision brain medicine to patients, physicians, and partners in the US and worldwide.”

What to watch

The first signal is whether Omniscient announces a formal partnership with one of the clinical-stage BCI implant companies. The current expansion language is generic (“BCI markets”), but a named partnership with an implant company would convert the adjacency narrative into a commercial line. The second signal is the pace of CPT code 1039T adoption across US hospital networks. Reimbursement code adoption typically lags the regulatory clearance by 12 to 24 months, and the speed of US hospital uptake will determine whether the recurring revenue model materialises at the pace the Series D is priced against. The third signal is whether the NRFC’s involvement leads to additional Australian government anchor capital flowing into the broader Australian neurotech cluster (Synchron, Cortical Labs, Brain Foundation Australia, the Florey Institute), which would mark a structural shift in how Australian sovereign capital interacts with the neurotechnology category.

Sources

• Omniscient Secures USD 27.2M Series D to Accelerate Commercialization of AI-Enabled Brain Technology (Globe Newswire / Omniscient Neurotechnology, 29 May 2026)
• Omniscient Neurotechnology launches Quicktome brain-mapping platform after FDA clearance (NeuroNews, 2021)
• Omniscient Neurotechnology corporate site
• Hackensack Meridian Neuroscience Institute Now Using Quicktome (Hackensack Meridian Health, 2023)